Kallikrein-Related Peptidase 5

Handbook of Proteolytic Enzymes

Volumn 3, Issue , 2013, Pages 2772-2778

  Goettig, Peter ^a   Magdolen, Viktor ^b  

^a UNIVERSITY OF SALZBURG   (Austria)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884839489     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-382219-2.00611-6     Document Type: Chapter

References (63)

1. Suzuki Y., Nomura J., Hori J., Koyama J., Takahashi M., Horii I. Detection and characterization of endogenous protease associated with desquamation of stratum corneum. Arch. Dermatol. Res. 1993, 285(6):372-377.
2. Suzuki Y., Koyama J., Moro O., Horii I., Kikuchi K., Tanida M., Tagami H. The role of two endogenous proteases of the stratum corneum in degradation of desmoglein-1 and their reduced activity in the skin of ichthyotic patients. Br. J. Dermatol. 1996, 134(3):460-464.
3. Brattsand M., Egelrud T. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J. Biol. Chem. 1999, 274(42):30033-30040.
4. Yousef G.M., Diamandis E.P. The New Kallikrein-like Gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation. J. Biol. Chem. 1999, 274(53):37511-37516.
5. Yousef G.M., Kapadia C., Polymeris M.-E., Borgoño C., Hutchinson S., Wasney G.A., Soosaipillai A., Diamandis E.P. The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 2003, 1628(2):88-96.
6. Emami N., Diamandis E.P. Utility of Kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin. Chem. 2008, 54(10):1600-1607.
7. Lundwall A., Band V., Blaber M., Clements J.A., Courty Y., Diamandis E.P., Fritz H., Lilja H., Malm J., Maltais L.J., Olsson A.Y., Petraki C.D., Scorilas A., Sotiropoulou G., Stenman U.H., Stephan C., Talieri M., Yousef G.M. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol. Chem. 2006, 387(6):637-641.
8. Michael I.P., Sotiropoulou G., Pampalakis G., Magklara A., Ghosh M., Wasney G., Diamandis E.P. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J. Biol. Chem. 2005, 280(15):14628-14635. [Epub 2005 Feb 15].
9. Brattsand M., Stefansson K., Lundh C., Haasum Y., Egelrud T. A proteolytic cascade of kallikreins in the stratum corneum. J. Invest. Dermatol. 2005, 124(1):198-203.
10. Debela M., Magdolen V., Schechter N., Valachova M., Lottspeich F., Craik C.S., Choe Y., Bode W., Goettig P. Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J. Biol. Chem. 2006, 281(35):25678-25688.
11. Borgoño C.A., Gavigan J.A., Alves J., Bowles B., Harris J.L., Sotiropoulou G., Diamandis E.P. Defining the extended substrate specificity of kallikrein 1-related peptidases. Biol. Chem. 2007, 388(11):1215-1225.
12. Yamasaki K., Schauber J., Coda A., Lin H., Dorschner R.A., Schechter N.M., Bonnart C., Descargues P., Hovnanian A., Gallo R.L. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 2006, 20(12):2068-2080.
13. Mukai S., Fukushima T., Naka D., Tanaka H., Osada Y., Kataoka H. Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases. FEBS Journal 2008, 275(5):1003-1017.
14. Oikonomopoulou K., Hansen K.K., Saifeddine M., Tea I., Blaber M., Blaber S.I., Scarisbrick I., Andrade-Gordon P., Cottrell G.S., Bunnett N.W., Diamandis E.P., Hollenberg M.D. Proteinase-activated receptors, targets for kallikrein signalling. J. Biol. Chem. 2006, 281(43):32095-32112.
15. Yoon H., Laxmikanthan G., Lee J., Blaber S.I., Rodriguez A., Kogot J.M., Scarisbrick I.A., Blaber M. Activation profiles and regulatory cascades of the human kallikrein-related peptidases. J. Biol. Chem. 2007, 282(44):31852-31864.
16. Michael I.P., Pampalakis G., Mikolajczyk S.D., Malm J., Sotiropoulou G., Diamandis E.P. Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. J. Biol. Chem. 2006, 281(18):12743-12750. [Epub 2006 Mar 3].
17. Debela M., Goettig P., Magdolen V., Huber R., Schechter N.M., Bode W. Structural basis of the zinc inhibition of human tissue Kallikrein 5. J. Mol. Biol. 2007, 373(4):1017-1031.
18. Luo L.-Y., Jiang W. Inhibition profiles of human tissue kallikreins by serine protease inhibitors. Biol. Chem. 2006, 387(6):813-816.
19. Egelrud T., Brattsand M., Kreutzmann P., Walden M., Vitzithum K., Marx U.C., Forssmann W.G., Magert H.J. hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. Br. J. Dermatol. 2005, 153(6):1200-1203.
20. Schechter N.M., Choi E.J., Wang Z.M., Hanakawa Y., Stanley J.R., Kang Y., Clayman G.L., Jayakumar A. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol. Chem. 2005, 386(11):1173-1184.
21. Borgoño C.A., Michael I.P., Komatsu N., Jayakumar A., Kapadia R., Clayman G.L., Sotiropoulou G., Diamandis E.P. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J. Biol. Chem. 2007, 282(6):3640-3652.
22. Deraison C., Bonnart C., Lopez F., Besson C., Robinson R., Jayakumar A., Wagberg F., Brattsand M., Hachem J.P., Leonardsson G., Hovnanian A. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol. Biol. Cell 2007, E07-02-0124.
23. Brattsand M., Stefansson K., Hubiche T., Nilsson S.K., Egelrud T. SPINK9: a selective, skin-specific kazal-type serine protease inhibitor. J. Invest. Dermatol. 2009, 129(7):1656-1665.
24. Meyer-Hoffert U., Wu Z., Schröder J.-M. Identification of lympho-epithelial kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor. PLoS ONE 2009, 4(2):e4372.
25. Meyer-Hoffert U., Wu Z., Kantyka T., Fischer J., Latendorf T., Hansmann B., Bartels J., He Y., Gläser R., Schröder J.M. Isolation of SPINK6 in human skin: selective inhibitor of kallikrein-related peptidases. J. Biol. Chem. 2010, 285(42):32174-32181.
26. Bode W., Chen Z., Bartels K., Kutzbach C., Schmidt-Kastner G., Bartunik H. Refined 2 A X-ray crystal structure of porcine pancreatic kallikrein A, a specific trypsin-like serine proteinase. Crystallization, structure determination, crystallographic refinement, structure and its comparison with bovine trypsin. J. Mol. Biol. 1983, 164(2):237-282.
27. Bode W., Schwager P. The single calcium-binding site of crystallin bovin beta-trypsin. FEBS Lett. 1975, 56(1):139-143.
28. Fujinaga M., James M.N. Rat submaxillary gland serine protease, tonin. Structure solution and refinement at 1.8 A resolution. J. Mol. Biol. 1987, 195(2):373-396.
29. Bode W., Turk D., Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci. 1992, 1(4):426-471.
30. Debela M., Beaufort N., Magdolen V., Schechter N.M., Craik C.S., Schmitt M., Bode W., Goettig P. Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biol. Chem. 2008, 389(6):623-632.
31. Yousef G.M., Polymeris M.-E., Grass L., Soosaipillai A., Chan P.-C., Scorilas A., Borgoño C., Harbeck N., Schmalfeldt B., Dorn J., Schmitt M., Diamandis E.P. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Research 2003, 63(14):3958-3965.
32. Pavlopoulou A., Pampalakis G., Michalopoulos I., Sotiropoulou G. Evolutionary history of tissue kallikreins. PLoS ONE 2010, 5(11):e13781.
33. Shaw J.L.V., Diamandis E.P. Distribution of 15 human kallikreins in tissues and biological fluids. Clin. Chem. 2007, 53(8):1423-1432.
34. Gan L., Lee I., Smith R., Argonza-Barrett R., Lei H., McCuaig J., Moss P., Paeper B., Wang K. Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene 2000, 257(1):119-130.
35. Paliouras M., Diamandis E. Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines. Breast Cancer Res. Treat. 2007, 102(1):7-18.
36. Caubet C., Jonca N., Brattsand M., Guerrin M., Bernard D., Schmidt R., Egelrud T., Simon M., Serre G. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol. 2004, 122(5):1235-1244.
37. Suzuki Y., Nomura J., Koyama J., Horii I. The role of proteases in stratum corneum: involvement in stratum corneum desquamation. Arch. Dermatol. Res. 1994, 286(5):249-253.
38. Descargues P., Deraison C., Prost C., Fraitag S., Mazereeuw-Hautier J., D'Alessio M., Ishida-Yamamoto A., Bodemer C., Zambruno G., Hovnanian A. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton Syndrome. J. Invest. Dermatol. 2006, 126(7):1622-1632.
39. Ekholm I.E., Brattsand M., Egelrud T. Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process?. J. Invest. Dermatol. 2000, 114(1):56-63.
40. Shaw J.L.V., Diamandis E.P. A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology. Biol. Chem. 2008, 389(6):681-688.
41. Chavanas S., Bodemer C., Rochat A., Hamel-Teillac D., Ali M., Irvine A.D., Bonafe J.-L., Wilkinson J., Taieb A., Barrandon Y., Harper J.I., de Prost Y., Hovnanian A. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat. Genet. 2000, 25(2):141-142.
42. Komatsu N., Saijoh K., Jayakumar A., Clayman G.L., Tohyama M., Suga Y., Mizuno Y., Tsukamoto K., Taniuchi K., Takehara K., Diamandis E.P. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J. Invest. Dermatol. 2008, 128(5):1148-1159.
43. Komatsu N., Saijoh K., Kuk C., Liu A.C., Khan S., Shirasaki F., Takehara K., Diamandis E.P. Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. Exp. Dermatol. 2007, 16(6):513-519.
44. Komatsu N., Saijoh K., Kuk C., Shirasaki F., Takehara K., Diamandis E.P. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. Br. J. Dermatol. 2007, 156(5):875-883.
45. Thomas A.C., Tattersall D., Norgett E.E., O'Toole E.A., Kelsell D.P. Premature terminal differentiation and a reduction in specific proteases associated with loss of ABCA12 in Harlequin ichthyosis. Am. J. Pathol. 2009, 174(3):970-978.
46. Stefansson K., Brattsand M., Roosterman D., Kempkes C., Bocheva G., Steinhoff M., Egelrud T. Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. J. Invest. Dermatol. 2008, 128(1):18-25.
47. Kim H., Scorilas A., Katsaros D., Yousef G.M., Massobrio M., Fracchioli S., Piccinno R., Gordini G., Diamandis E.P. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br. J. Cancer 2001, 84:643-650.
48. Diamandis E.P., Borgoño C.A., Scorilas A., Yousef G.M., Harbeck N., Dorn J., Schmalfeldt B., Schmitt M. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Tumour Biol. 2003, 24(6):299-309.
49. Dorn J., Magdolen V., Gkazepis A., Gerte T., Harlozinska A., Sedlaczek P., Diamandis E.P., Schuster T., Harbeck N., Kiechle M., Schmitt M. Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients survival. Annals of Oncology 2011, accepted for publication 1-8.
50. Bandiera E., Zanotti L., Bignotti E., Romani C., Tassi R., Todeschini P., Tognon G., Ragnoli M., Santin A.D., Gion M., Pecorelli S., Ravaggi A. Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. Int. J. Gynecol. Cancer 2009, 19(6):1015-1021.
51. Dorn J., Harbeck N., Kates R., Gkazepis A., Scorilas A., Soosaipillai A., Diamandis E., Kiechle M., Schmalfeldt B., Schmitt M. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Annals of Oncology 2010, 22(4):877-883.
52. Planque C., de Monte M., Guyetant S., Rollin J., Desmazes C., Panel V., Lemarié E., Courty Y. KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer. Biochem. Biophys. Res. Commun. 2005, 329(4):1260-1266.
53. Pettus J.R., Johnson J.J., Shi Z., Davis J.W., Koblinski J., Ghosh S., Liu Y., Ravosa M.J., Frazier S., Stack M.S. Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity. Histol. Histopathol. 2009, 24(2):197-207.
54. Talieri M., Li L., Zheng Y., Alexopoulou D.K., Soosaipillai A., Scorilas A., Xynopoulos D., Diamandis E.P. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br. J. Cancer 2009, 100(10):1659-1665.
55. Jiang R., Shi Z., Johnson J.J., Liu Y., Stack M.S. Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma. J. Biol. Chem. 2011, 286:9127-9135.
56. Yousef G.M., Obiezu C.V., Jung K., Stephan C., Scorilas A., Diamandis E.P. Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. Urology 2002, 60(4):714-718.
57. Yousef G.M., Scorilas A., Chang A., Rendl L., Diamandis M., Jung K., Diamandis E.P. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. The Prostate 2002, 51(2):126-132.
58. Yousef G.M., Scorilas A., Kyriakopoulou L.G., Rendl L., Diamandis M., Ponzone R., Biglia N., Giai M., Roagna R., Sismondi P., Diamandis E.P. Human kallikrein gene 5 (klk5) expression by Quantitative PCR: an independent indicator of poor prognosis in breast cancer. Clin. Chem. 2002, 48(8):1241-1250.
59. Lundwall A., Brattsand M. Kallikrein-related peptidases. Cell Mol. Life Sci. 2008, 65(13):2019-2038.
60. Goettig P., Magdolen V., Brandstetter H. Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie 2010, 92(11):1546-1567.
61. Eissa A., Diamandis E.P. Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions. Biol. Chem. 2008, 389(6):669-680.
62. Sotiropoulou G., Pampalakis G., Diamandis E.P. Functional roles of human kallikrein-related peptidases. J. Biol. Chem. 2009, 284(48):32989-32994.
63. Paliouras M., Borgoño C., Diamandis E.P. Human tissue kallikreins: The cancer biomarker family. Cancer Lett. 2007, 249(1):61-79.